International Flavors & Fragrances
INTERNATIONAL FLAVORS & FRAGRANCES INC
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$10.9B
Operating marginCalculated
-3.5%
Net assets to total assetsCalculated
55.4%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★☆☆☆☆position among all companies
-3.5%
Growth (revenue, 4-year average)
★☆☆☆☆position among all companies
-1.7%
Capital efficiency
Could not be retrieved
Revenue and profit
Performance, financial position and capital allocation
International Flavors & Fragrances
Recent performance trends
International Flavors & Fragrances
Cash flow trends
Consolidated indicators (8 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$11.7 billion | US$12.4 billion | US$11.5 billion | US$11.5 billion | US$10.9 billion |
| Operating income | US$0.6 billion | US$-1.3 billion | US$-2.1 billion | US$0.8 billion | US$-0.4 billion |
| Total assets | US$39.7 billion | US$35.5 billion | US$31.0 billion | US$28.7 billion | US$25.5 billion |
| Shareholders' equity | US$21.1 billion | US$17.7 billion | US$14.6 billion | US$13.8 billion | US$14.2 billion |
| Net cash provided by (used in) operating activities | US$1.4 billion | US$0.4 billion | US$1.5 billion | US$1.1 billion | US$0.8 billion |
| Net cash provided by (used in) investing activities | US$-18.00 million | US$0.7 billion | US$0.6 billion | US$0.3 billion | US$2.3 billion |
| Net cash provided by (used in) financing activities | US$-1.3 billion | US$-1.2 billion | US$-1.9 billion | US$-1.6 billion | US$-3.1 billion |
| Cash and cash equivalents | US$0.7 billion | US$0.5 billion | US$0.7 billion | US$0.5 billion | US$0.6 billion |
Revenue scale in the same industry
International Flavors & Fragrances
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDFY Dec 2025 US$65.2B
- … 19 companies
- 23 Vertex Pharmaceuticals INC / MAFY Dec 2025 US$12.0B
- 24 WestlakeFY Dec 2025 US$11.2B
- 25 International Flavors & FragrancesThis companyFY Dec 2025 US$10.9B
- 26 BiogenFY Dec 2025 US$9.9B
- 27 CelaneseFY Dec 2025 US$9.5B
- … 29 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.6 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.6 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-3.1 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$2.3 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$0.8 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$1.0 billion | Consolidated | Disclosed |
| Dividends paid | US$0.4 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$14.2 billion | Consolidated | Disclosed |
| Non-controlling interests | US$32.00 million | Consolidated | Disclosed |
| Net assets | US$14.2 billion | Consolidated | Disclosed |
| Net sales | US$10.9 billion | Consolidated | Disclosed |
| Operating income | US$-0.4 billion | Consolidated | Disclosed |
| Total assets | US$25.5 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$38.00 million | Consolidated | Disclosed |
| Operating margin | -3.5% | Consolidated | Calculated |
| Net assets to total assets | 55.4% | Consolidated | Calculated |
| Net margin | Cannot be calculated | Not applicable | Not calculated (no net income in this year's 10-K) |
| Return on equity | Cannot be calculated | Not applicable | Not calculated (no net income in this year's 10-K) |